Drug Profile

Research programme: genetic cardiomyopathy therapeutics - MyoKardia/Fulcrum Therapeutics

Latest Information Update: 10 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

08 Feb 2023 Preclinical trials in Cardiomyopathies in USA (unspecified route) as of February 2023 (Fulcrum Therapeutics pipeline, February 2023)
17 Nov 2020 MyoKardia has been acquired by Bristol-Myers Squibb
22 Jul 2020 MyoKardia and Fulcrum Therapeutics agree to co-promote and co-develop therapeutics for genetic cardiomyopathies

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com